Recombinant human protein was used as the immunogen for this DOG1 antibody.
Expression of TMEM16A (DOG1) protein is elevated in the gastrointestinal stromal tumors (GISTs), c-kit signaling-driven mesenchymal tumors of the GI tract. It is rarely expressed in other soft tissue tumors, which, due to appearance, may be difficult to diagnose. Immunoreactivity for DOG11 has been reported in 97.8 percent of scorable GISTs, including all c-kit negative GISTs. Overexpression has been suggested to aid in the identification of GISTs, including Platelet-Derived Growth Factor Receptor Alpha (PDGFR alpha) mutants that fail to express c-kit antigen. The overall sensitivity of TMEM16A and c-kit in GISTs is nearly identical: 94.4% vs. 94.7%.
Klonalität:
Monoclonal
Konzentration:
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
Reinheit:
Protein G affinity chromatography
Formulierung:
0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide
Target-Kategorie:
DOG1
Antibody Type:
Primary Antibody
Application Verdünnung:
Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT,Prediluted IHC only format: incubate for 30 min at RT (1)
Anwendungsbeschreibung:
Titering of the DOG1 antibody may be required for optimal performance.1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
